PepGen Inc. (PEPG) 10-Year Financial Performance & Capital Metrics

PEPG • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$96M -15.1%
Net Income -$90M -14.4%
EPS (Diluted) -2.85 +13.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -79.26% -45.2%
ROIC -108.11% +40.3%
Debt/Equity 0.16 -15.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)
✓Trading at only 1.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 32.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7.25%

EPS CAGR

10Y-

5Y-

3Y-

TTM41.28%

ROCE

10Y Avg-44.85%

5Y Avg-46.81%

3Y Avg-56.24%

Latest-75.27%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	106K	0	0	0	1.18M	1.5M
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-106K	0	0	0	-1.18M	-1.5M
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-	-0.27%
Operating Expenses+	1.25M	1.88M	27.11M	68.3M	83.58M	96.23M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	628K	853K	8.11M	14.22M	16.64M	21.26M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	620K	1.12M	23.8M	54.08M	68.13M	76.48M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	-100K	-4.8M	0	-1.18M	-1.5M
Operating Income+	-1.35M	-1.88M	-27.11M	-68.3M	-84.77M	-97.74M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.39%	-13.44%	-1.52%	-0.24%	-0.15%
EBITDA+	-1.25M	-1.77M	-26.93M	-67.81M	-83.58M	-96.23M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-0.42%	-14.24%	-1.52%	-0.23%	-0.15%
D&A (Non-Cash Add-back)	106K	110K	178K	493K	1.18M	1.5M
EBIT	-1.35M	-1.88M	-27.11M	-68.3M	-84.77M	-90.6M
Net Interest Income+	6K	8K	0	2.79M	6.4M	7.14M
Interest Income	6K	8K	0	2.79M	6.4M	7.14M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	8K	-12K	-172K	2.9M	6.21M	7.14M
Pretax Income+	-1.35M	-1.89M	-27.28M	-65.4M	-78.55M	-90.6M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	3.71M	73K	-617K
Effective Tax Rate %	1%	1%	1%	1.06%	1%	0.99%
Net Income+	-1.35M	-1.89M	-27.28M	-69.1M	-78.63M	-89.98M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.4%	-13.44%	-1.53%	-0.14%	-0.14%
Net Income (Continuing)	-1.35M	-1.89M	-27.28M	-69.1M	-78.63M	-89.98M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-0.18	-1.22	-4.42	-3.30	-2.85
EPS Growth %	-	-2%	-5.78%	-2.62%	0.25%	0.14%
EPS (Basic)	-0.06	-0.53	-1.22	-4.42	-3.30	-2.85
Diluted Shares Outstanding	22.39M	22.39M	22.39M	15.64M	23.8M	31.58M
Basic Shares Outstanding	22.39M	7.72M	22.39M	15.64M	23.8M	31.58M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.77M	10.32M	139.99M	186.08M	112.68M	123.76M
Cash & Short-Term Investments	3.49M	9.78M	132.9M	181.75M	110.41M	120.19M
Cash Only	3.49M	9.78M	132.9M	181.75M	80.77M	49.42M
Short-Term Investments	0	0	0	0	29.63M	70.77M
Accounts Receivable	230K	407K	4.74M	58K	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	4.27M	2.27M	3.57M
Total Non-Current Assets+	419K	323K	3.65M	31.36M	30.37M	27.12M
Property, Plant & Equipment	419K	323K	636K	29.88M	28.38M	25.15M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	1.47M	0	0	0
Other Non-Current Assets	0	0	1.55M	1.47M	1.99M	1.97M
Total Assets+	4.19M	10.64M	143.64M	217.44M	143.05M	150.88M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	1.54%	12.5%	0.51%	-0.34%	0.05%
Total Current Liabilities+	326K	838K	10.32M	18.83M	17.53M	16.7M
Accounts Payable	141K	721K	3.24M	1.36M	1M	1.75M
Days Payables Outstanding	485.52	-	-	-	309.82	424.9
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	28K	1.21M	2.44M	2.37M	3.62M
Current Ratio	11.58x	12.31x	13.56x	9.88x	6.43x	7.41x
Quick Ratio	11.58x	12.31x	13.56x	9.88x	6.43x	7.41x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	30K	226K	18.98M	17.1M	15.57M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	18.98M	17.1M	15.57M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	30K	226K	0	0	0
Total Liabilities	326K	868K	10.55M	37.81M	34.63M	32.26M
Total Debt+	0	0	0	24.53M	20.1M	18.66M
Net Debt	-3.49M	-9.78M	-132.9M	-157.22M	-60.67M	-30.76M
Debt / Equity	-	-	-	0.14x	0.19x	0.16x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	3.87M	9.77M	133.09M	179.63M	108.42M	118.62M
Equity Growth %	-	1.53%	12.62%	0.35%	-0.4%	0.09%
Book Value per Share	0.17	0.44	5.94	11.49	4.56	3.76
Total Shareholders' Equity	3.87M	9.77M	133.09M	179.63M	108.42M	118.62M
Common Stock	0	0	0	2K	2K	3K
Retained Earnings	-2.39M	-6.47M	-33.75M	-102.86M	-181.48M	-271.46M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-8K	-8K	17K	-81K	34K	23K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-885K	-1.65M	-22.6M	-59.27M	-69M	-82.37M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.87%	-12.68%	-1.62%	-0.16%	-0.19%
Net Income	-1.35M	-1.89M	-27.28M	-69.1M	-78.63M	-89.98M
Depreciation & Amortization	106K	110K	178K	493K	850K	5.25M
Stock-Based Compensation	0	119K	1.53M	4.76M	7.05M	11.46M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	59K	0	196K	76K	-220K	-3.85M
Working Capital Changes	296K	8K	2.77M	4.51M	1.95M	-5.25M
Change in Receivables	-112K	-170K	-4.34M	4.18M	26K	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	59K	331K	2.51M	-1.41M	-369K	722K
Cash from Investing+	-29K	-8K	-500K	-3.75M	-32M	-37.67M
Capital Expenditures	-29K	-8K	-500K	-3.75M	-2.6M	-497K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	2.79M	7.95M	147.66M	112.19M	-189K	88.75M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	-3K	-1.39M	-2.07M	-189K	1.97M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-914K	-1.66M	-23.1M	-63.02M	-71.6M	-82.87M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.82%	-12.92%	-1.73%	-0.14%	-0.16%
FCF per Share	-0.04	-0.07	-1.03	-4.03	-3.01	-2.62
FCF Conversion (FCF/Net Income)	0.66x	0.87x	0.83x	0.86x	0.88x	0.92x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	2.7M	71K

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-34.81%	-27.7%	-38.19%	-44.19%	-54.59%	-79.26%
Return on Invested Capital (ROIC)	-	-756.85%	-20853.08%	-453.08%	-181.22%	-108.11%
Debt / Equity	-	-	-	0.14x	0.19x	0.16x
FCF Conversion	0.66x	0.87x	0.83x	0.86x	0.88x	0.92x

Frequently Asked Questions

Growth & Financials

PepGen Inc. (PEPG) grew revenue by 0.0% over the past year. Growth has been modest.

PepGen Inc. (PEPG) reported a net loss of $93.6M for fiscal year 2024.

Dividend & Returns

PepGen Inc. (PEPG) has a return on equity (ROE) of -79.3%. Negative ROE indicates the company is unprofitable.

PepGen Inc. (PEPG) had negative free cash flow of $85.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener